The case for & against
Bull & Bear analysis
Bullish
Bayer AG (BAYRY) is a global life sciences company that operates primarily in the fields of healthcare and agriculture. The Crop Science division, which includes the former Monsanto operations, focuses on providing innovative solutions, seeds, and crop protection products. Bayer is recognized for its significant contributions to agriculture through sustainable practices and technology, particularly with its herbicides like glyphosate and biotechnology products. The company is currently navigating ongoing litigation related to the Roundup product, which affects its market perception and financial outlook.
Bull says
- ↑Q2 2026 adjusted EBITDA €2.14B beat estimates, led by Crop Science
- ↑Soybean sales +17% and glyphosate +13% YoY indicate strong demand
- ↑U.S. Supreme Court June ruling and settlement dismissals limit litigation costs
- ↑Pipeline of 10 new products targeting >€500M peak sales each
- ↑Aims for €1B EBITDA improvement in Crop Science by 2030
- ↑High earnings yield, strong ROE, growth momentum, and solid balance sheet support upside
Bear says
- ↓~65K remaining Roundup claims could trigger adverse judgments or large settlements
- ↓Legal overhang sustains high stock volatility and weak investor sentiment
- ↓Glyphosate scrutiny and regulatory shifts threaten core Crop Science revenues
- ↓Current valuation may not reflect potential litigation liabilities, risking rerating
- ↓High short interest and volatility factor signal market skepticism
- ↓Negative earnings yield concern relative to peers could deter returns